US4722840A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Hybrid particle immunogens
Assignee: Novartis Vaccines and Diagnostics Inc
•
Filing: 1985-09-19
•
Granted: 1988-02-02
•
Expires: 2005-09-19
Abstract
Abstract Novel immunogenic compositions are provided involving viral particles composed at least in part of hybrid proteins of at least a portion of a particle forming protein and one or more polypeptides having at least one epitope of interest. Nucleic acid sequences are employed coding for the hybrid protein which are introduced into a host cell for expression, either by themselves or in combination with other DNA sequences coding for particle forming proteins. Expression of the DNA sequences results in formation of particles which may be isolated and used as immunogens for production of antibodies for diagnostics purposes, passive immunization, vaccination, or other uses. Saccharomyces carlsbergensis, 2150-2-3 (pDC103), was deposited on Sept. 7, 1984, at the ATCC and given ATCC Accession No. 20726. Also, Saccharomyces cerevisiae PO17 (pC1/1-MCS29) was deposited at the ATCC on Sept. 5, 1985, and given ATCC Accession No. 20770.
Inventors
- 👤 Pablo D. T. Valenzuela
- 👤 George Kuo
- 👤 Philip J. Barr
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 09:17
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/005; A; A61; A61K; A61K39/00; A61K39/002; A61K39/015; A61K39/12; A61K39/245; A61K39/385; A61P; A61P37/00; A61P37/02; A61P37/04; C07K14/435; C07K14/44; C07K14/445; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/62; C12N15/63; C12N15/79; C12N15/80; C12N15/81; A61K2039/60; A61K2039/6031; A61K2039/6075; C07K2319/00; C07K2319/40; C07K2319/70; C07K2319/735; C12N2710/00; C12N2710/00011; C12N2710/16011; C12N2710/16611; C12N2710/16622; C12N2710/16634; C12N2710/16711; C12N2710/16722; C12N2730/00; C12N2730/00011; C12N2730/10011; C12N2730/10111; C12N2730/10122; Y; Y02; Y02A; Y02A50/00; Y02A50/30; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/22; Y10S930/223; Y10S930/31
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
58 words
A hybrid polypeptide comprising an assembled particle, said hybrid polypeptide comprised of a particle-forming fragment of a structural protein from a virus particle fused to a heterologous amino acid sequence defining an eptopic site of a pathogen or toxin, said heterologous amino acid sequence being disposed within said assembled particle such that said eptopic site is immunologically reactive.
Claim 2
Dependent Claim
58 words
A hybrid polypeptide comprising an assembled particle, said hybrid polypeptide comprised of a particle-forming fragment of a structural protein from a virus particle fused to a heterologous amino acid sequence defining an eptopic site of a pathogen or toxin, said heterologous amino acid sequence being disposed within said assembled particle such that said eptopic site is immunologically reactive.
Claim 3
Dependent Claim
19 words
A hybrid polypeptide according to claim 1, wherein said particle forming polypeptide is derived from Hepatitis B surface antigen.
Claim 4
Dependent Claim
33 words
A hybrid polypeptide according to claim 2, wherein said polypeptides of interest are linked to said particle forming polypeptide through at least a portion of the pre-surface polypeptide of Hepatitis B surface antigen.
Claim 5
Dependent Claim
20 words
A hybrid polypeptide according to claim 3, wherein at least about 25 amino acids of said pre-surface polypeptide are present.
Claim 6
Dependent Claim
14 words
A hybrid polypeptide according to claim 1, wherein said host is a unicellular microorganism.
Claim 7
Dependent Claim
13 words
A hybrid polypeptide according to claim 1, wherein said host is mammalian cell.
Claim 8
Dependent Claim
22 words
A hybrid polypeptide according to claim 1, wherein at least one of said polypeptides of interest is an oligopeptide of a pathogen.
Claim 9
Dependent Claim
18 words
A hybrid polypeptide according to claim 7, wherein one of said polypeptides of interest is an envelope polypeptide.
Claim 10
Dependent Claim
50 words
A novel hybrid polypeptide comprising at least a major portion of the Hepatitis B surface antigen fused to one or more oligopeptides, where the hybrid polypeptide is capable of forming a particle in a cellular host upon expression with presentation of at least one epitope of at lest one oligopeptide.
Claim 11
Dependent Claim
50 words
A novel hybrid polypeptide comprising at least a major portion of the Hepatitis B surface antigen fused to one or more oligopeptides, where the hybrid polypeptide is capable of forming a particle in a cellular host upon expression with presentation of at least one epitope of at lest one oligopeptide.
Claim 12
Dependent Claim
15 words
A hybrid polypeptide according to claim 9, wherein said epitope is specific for a pathogen.
Claim 13
Dependent Claim
16 words
A hybrid polypeptide according to claim 10, wherein said epitope is present on an envelope protein.
Claim 14
Dependent Claim
39 words
A novel hybrid polypeptide comprising Hepatitis B surface antigen linked to an eptopic region of the envelope D protein of Herpes Simplex virus or a circumsporozite protein of Plasmodium falciparum through at least a portion of the pre-surface polypeptide.
Claim 15
Dependent Claim
39 words
A novel hybrid polypeptide comprising Hepatitis B surface antigen linked to an eptopic region of the envelope D protein of Herpes Simplex virus or a circumsporozite protein of Plasmodium falciparum through at least a portion of the pre-surface polypeptide.
Claim 16
Dependent Claim
14 words
A polyvalent vaccine comprising the polypeptide of any of claims 7, 10 or 12.
References Cited (Backward Citations)
US4164565A
Cited
US4113712A
Cited
US4349629A
Cited
US4428941A
Cited
US4554157A
Cited
US4551433A
Cited
US4593002A
Cited
US4572894A
Cited
US4575495A
Cited
US4493795A
Cited
US4599230A
Cited
US4599231A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-02-01 | 1991-08-03 | 1992-02-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-02-01 | 1995-08-03 | 1996-02-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-02-01 | 1999-08-03 | 2000-02-02 | $7700.00 | Window Closed / Lapsed |